NewEdge Advisors’s Bio-Rad Laboratories Class A BIO Stock Holding History
Bought
Maintained
Sold
Other funds holding BIO
NewEdge Advisors's BIO Position: Q3 2026 in Review
NewEdge Advisors increased its Bio-Rad Laboratories Class A (BIO) stake by 1.1% in Q3 2026, buying an estimated $349 and bringing the position to 92 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #3259.
NewEdge Advisors first reported a position in BIO in Q3 2020 and has held it in 20 quarters since. The position peaked at $1.31M in Q1 2023. 417 funds tracked by Wall St. Rank hold BIO as of Q3 2026.
- NewEdge Advisors held 92 shares of Bio-Rad Laboratories Class A worth $34.7K as of Q3 2026.
- NewEdge Advisors bought 1 Bio-Rad Laboratories Class A share in Q3 2026, an estimated $349.
- Bio-Rad Laboratories Class A made up ﹤0.01% of NewEdge Advisors's portfolio in Q3 2026, its #3259 holding.
- NewEdge Advisors first reported a position in Bio-Rad Laboratories Class A in Q3 2020 and has held it in 20 quarters since.
- NewEdge Advisors's Bio-Rad Laboratories Class A position peaked at $1.31M in Q1 2023.
- 417 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2026.
Based on NewEdge Advisors's 13F filing for Q3 2026, filed 13 Nov 2026.